Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies [Phase 2]
Phase 2 trial update evaluating PDR001 plus LAG525 in patients with advanced solid and hematologic malignancies; results posted with complet…
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients [Phase 1]
Phase 1/open-label pharmacokinetic study assessing interactions between tazemetostat and CYP enzymes and gastric pH in patients with B-cell …
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ [Phase 3]
Phase 3 trial evaluating lenalidomide with subcutaneous rituximab plus miniCHOP in elderly patients with Diffuse Large B-Cell Lymphoma has c…
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study [Phase 2]
Phase II open-label multicenter trial of R2-CHOP in untreated DEL-DLBCL.
-
CLINICAL_TRIALS trial_result · 2021-04-01Clinical Trial Update: A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 study evaluating anlotinib hydrochloride capsules in sujets with diffuse large B-cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: Early Palliative Care for Patients With Haematological Malignancies [Phase 3]
Phase 3 clinical trial update on early palliative care for patients with hematologic malignancies including acute myeloid leukemia and myelo…
-
CLINICAL_TRIALS trial_result · 2021-03-16Clinical Trial Update: PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT [Phase 3]
Phase 3 trial evaluating maintenance therapy with the PD-1 inhibitor tislelizumab in relapsed/refractory diffuse large B-cell lymphoma after…
-
CLINICAL_TRIALS trial_result · 2021-03-15Clinical Trial Update: Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL [Phase 1, Phase 2]
Clinical trial update investigating camrelizumab combined with apatinib in relapsed/refractory diffuse large B-cell lymphoma, covering Phase…
-
CLINICAL_TRIALS trial_result · 2021-03-01Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) [Phase 1]
Phase 1 study of pembrolizumab in combination with dinaciclib in hematologic malignancies was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-17Clinical Trial Update: Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL [Phase 2]
Phase 2 clinical trial evaluating the safety and efficacy of iR2 in untreated and unfit elderly patients with Diffuse Large B-Cell Lymphoma …
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation [Phase 2]
Phase 2 trial comparing Zevalin/BEAM/Rituximab versus BEAM/Rituximab with or without Rituximab as conditioning for autologous stem cell tran…
-
CLINICAL_TRIALS trial_result · 2021-01-06Clinical Trial Update: A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib plus vistusertib in relapsed/refractory B-cell malignancies (DLBCL and Richter syndrome) was terminated.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) [Phase 3]
Phase 3 trial in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-12-09Clinical Trial Update: Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL [Phase 2]
Phase 2 clinical trial investigating sintilimab plus R-GemOx as second-line salvage therapy for relapsed/refractory diffuse large B-cell lym…
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD20 radioimmunotherapy before chemotherapy and stem cell transplant in high-risk B-cell malignancies; trial s…
-
CLINICAL_TRIALS trial_result · 2020-11-19Clinical Trial Update: Biomarker Guided Treatment in DLBCL [Phase 2]
Phase 2 clinical trial update evaluating biomarker-guided treatment in Diffuse Large B Cell Lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-11-10Clinical Trial Update: Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years [Phase 2]
A Phase 2 trial evaluating lenalidomide with rituximab as front-line therapy for diffuse large B-cell lymphoma in patients over 80 years old…
-
CLINICAL_TRIALS trial_result · 2020-11-05Clinical Trial Update: An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating AZD2014 alone and with rituximab in relapsed/refractory diffuse large B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2020-11-05Clinical Trial Update: GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial of GA101-miniCHOP regimen for elderly unfit patients with CD20-positive diffuse large B-cell lymphoma; study terminated with r…
-
CLINICAL_TRIALS trial_result · 2020-10-23Clinical Trial Update: Bortezomib Maintenance in High Risk DLBCL [Phase 2]
Phase 2 trial update on bortezomib maintenance in high-risk diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab with combination chemotherapy in older patients with diffuse large B-cell lymphoma has completed and resu…
-
CLINICAL_TRIALS trial_result · 2020-09-23Clinical Trial Update: Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies [Phase 2]
Phase 2 study evaluating entospletinib in adults with relapsed or refractory hematologic malignancies; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2020-09-23Clinical Trial Update: Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating pembrolizumab with combination chemotherapy in untreated diffuse large B-cell lymphoma and grade 3b follicular lymp…
-
CLINICAL_TRIALS trial_result · 2020-09-16Clinical Trial Update: TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]
Phase 2 trial update for TAK-659 in relapsed or refractory diffuse large B-cell lymphoma has been terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-09-11Clinical Trial Update: Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT) [Phase 2]
Phase 2 trial evaluating blinatumomab on minimal residual disease in high-risk diffuse large B-cell lymphoma after autologous stem cell tran…